Pharmacological profiles and clinical effects of olmesartan medoxomil, a novel angiotensin II receptor blocker

Folia Pharmacologica Japonica

Volumn 124, Issue 4, 2004, Pages 257-269

  Sada, Toshio ^a   Mizuno, Makoto ^a  

^a DAIICHI SANKYO CO   (Japan)

Author keywords

Angiotensin II receptor blocker; Antihypertensive effect; Olmesartan; Olmesartan medoxomil; Organ protection

Indexed keywords

2 BUTYL 4 CHLORO 1 [[2' (1H TETRAZOL 5 YL) 4 BIPHENYLYL]METHYL] 5 IMIDAZOLECARBOXYLIC ACID; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; CANDESARTAN; CANDESARTAN HEXETIL; CYTOCHROME P450; LOSARTAN; OLMESARTAN; PLACEBO; PRAVASTATIN; RECEPTOR SUBTYPE; TELMISARTAN; VALSARTAN;

ANTIHYPERTENSIVE ACTIVITY; BLOOD PRESSURE; BLOOD VESSEL INJURY; DRUG EFFECT; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SELECTIVITY; DRUG TOLERABILITY; EUROPE; HEART INJURY; HUMAN; HYPERTENSION; IN VIVO STUDY; KIDNEY INJURY; NONHUMAN; REVIEW; TACHYCARDIA; UNITED STATES; VASCULAR TISSUE;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; ANTIHYPERTENSIVE AGENTS; HEART DISEASES; HUMANS; HYPERTENSION; IMIDAZOLES; KIDNEY DISEASES; PRODRUGS; TETRAZOLES; VASCULAR DISEASES;

EID: 7044224715     PISSN: 00155691     EISSN: None     Source Type: Journal    
DOI: 10.1254/fpj.124.257     Document Type: Review

References (36)

1. Staessen JA, Wang JG, Thijs L. Cardiovascular protection and blood pressure reduction: a metaanalysis. Lancet. 2001;358:1305-1315.
2. Yanagisawa H, Amemiya Y, Kanazaki T, Shimoji Y, Fujimoto K, Kitahara Y, et al. Nonpeptide angiotensin II receptor antagonists: synthesis, biological activities, and structure-activity relationships of imidazole-5-carboxylic acids bearing alkyl, alkenyl, and hydroxyalkyl substituents at the 4-position and their related compounds. J Med Chem. 1996;39:323-338.
3. Mizuno M, Sada T, Ikeda M, Fukuda N, Miyamoto M, Yanagisawa H, et al. Pharmacology of CS-866, a novel nonpeptide angiotensin II receptor antagonist. Eur J Pharmacol. 1995;285:181-188.
4. Koike H, Sada T, Mizuno M. In vitro and in vivo pharmacology of olmesartan medoxomil, an angiotensin II type AT1 receptor antagonist. J Hypertens. 2001;19 Suppl:S3-S14.
5. Koike H. New pharmacologic aspects of CS-866, the newest angiotensin II receptor antagonist. Am J Cardiol. 2001;87:33C-36C.
6. Koike H, Konse T, Sada T, Ikeda T, Hyogo A, Hinman D, et al. Olmesartan medoxomil, a novel potent angiotensin II blocker. Ann Rep Sankyo Res Lab. 2003;55:1-91.
7. Chilman-Blair K, Rabasseda X. Olmesartan, an AT 1-selective antihypertensive agent. Drugs Today. 2003;39:745-761.
8. Brousil JA, Burke JM. Olmesartan medoxomil: an angiotensin II-receptor blocker. Clin Ther. 2003;25: 1041-1055.
9. BIO Clinica. 2004;19: 524-528.
10. Brunner HR, Laeis P. Clinical efficacy of olmesartan medoxomil. J Hypertens. 2003;21 Suppl 2:S43-S46.
11. Kim S, Sada T, Mizuno M, Ikeda M, Yano M, Miura K, et al. Effects of angiotensin AT1 receptor antagonist on volume overload-induced cardiac gene expression in rats. Hypertens Res. 1997;20: 133-142.
12. Toko H, Oka T, Zou Y, Sakamoto M, Mizukami M, Sano M, et al. Angiotensin II type 1a receptor mediates doxorubicin-induced cardiomyopathy. Hypertens Res. 2002;25:597-603.
13. Taniyama Y, Morishita R, Nakagami H, Moriguchi A, Sakonjo H, Shokei-Kim, et al. Potential contribution of a novel antifibrotic factor, hepatocyte growth factor, to prevention of myocardial fibrosis by angiotensin II blockade in cardiomyopathic hamsters. Circulation. 2000;102:246-252.
14. Mizuno M, Sada T, Kato M, Koike H. Renoprotective effects of blockade of angiotensin II AT1 receptors in an animal model of type 2 diabetes. Hypertens Res. 2002;25:271-278.
15. Nangaku M, Miyata T, Sada T, Mizuno M, Inagi R, Ueda Y, et al. Anti-hypertensive agents inhibit in vivo the formation of advanced glycation end products and improve renal damage in a type 2 diabetic nephropathy rat model. J Am Soc Nephrol. 2003;14: 1212-1222.
16. Miyata T, van Ypersele de Strihou C, Ueda Y, Ichimori K, Inagi R, Onogi H, et al. Angiotensin II receptor antagonists and angiotensin-converting enzyme inhibitors lower in vitro the formation of advanced glycation end products: biochemical mechanisms. J Am Soc Nephrol. 2002;13:2478-2487.
17. Koga K, Yamagishi S, Takeuchi M, Inagaki Y, Amano S, Okamoto T, et al. CS-866, a new angiotensin II type 1 receptor antagonist, ameliorates glomerular anionic site loss and prevents progression of diabetic nephropathy in Otsuka Long-Evans Tokushima fatty rats. Mol Med. 2002;8:591-599.
18. Kim S, Izumi Y, Izumiya Y, Zhan Y, Taniguchi M, Iwao H. Beneficial effects of combined blockade of ACE and AT1 receptor on intimai hyperplasia in balloon-injured rat artery. Arterioscler Thromb Vasc Biol. 2002;22:1299-1304.
19. Mukai Y, Shimokawa H, Higashi M, Morikawa K, Matoba T, Hiroki J, et al. Inhibition of renin-angiotensin system ameliorates endothelial dysfunction associated with aging in rats. Arterioscler Thromb Vasc Biol. 2002;22:1445-1450.
20. Miyazaki M, Takai S. Anti-atherosclerotic efficacy of olmesartan. J Hum Hypertens. 2002;16 Suppl 2: S7-S12.
21. Takai S, Kim S, Sakonjo H, Miyazaki M. Mechanisms of angiotensin II type 1 receptor blocker for anti-atherosclerotic effect in monkeys fed a high-cholesterol diet. J Hypertens. 2003;21: 361-369.
22. Higashiura K, Ura N, Takada T, Li Y, Torii T, Togashi N, et al. The effects of an angiotensin-converting enzyme inhibitor and an angiotensin II receptor antagonist on insulin resistance in fructose-fed rats. Am J Hypertens. 2000;13:290-297.
23. Kurikawa N, Suga M, Kuroda S, Yamada K, Ishikawa H. An angiotensin II type 1 receptor antagonist, olmesartan medoxomil, improves experimental liver fibrosis by suppression of proliferation and collagen synthesis in activated hepatic stellate cells. Br J Pharmacol. 2003;139:1085-1094.
24. Yokoyama T, Inoue T, Nakamura H, Arakawa N, Shimizu Y. An angiotensin II type 1 receptor antagonist, olmesartan medoxomil, prevents mouse oxygen-induced retinopathy and VEGF-induced rabbit corneal neovascularization. Invest Ophthalmol Vis Sci. 2004;45:E-Abstract 1910.
25. Ichikawa S, Takayama Y. Long-term effects of olmesartan, an Ang II receptor antagonist, on blood pressure and the renin-angiotensin-aldosterone system in hypertensive patients. Hypertens Res. 2001;24:641-646.
26. Ball KJ, Williams PA, Stumpe KO. Relative efficacy of an angiotensin II antagonist compared with other antihypertensive agents. Olmesartan medoxomil versus antihypertensives. J Hypertens. 2001;19 Suppl 1:S49-S56.
27. Oparil S, Williams D, Chrysant SG, Marbury TC, Neutel J. Comparative efficacy of olmesartan, losartan, valsartan and irbesartan in the control of essential hypertension. J Clin Hypertens. 2001;3: 283-291.
28. Brunner HR, Stumpe KO, Januszewicz A. Antihypertensive efficacy of olmesartan medoxomil and candesartan cilexetil assessed by 24-hr ambulatory blood pressure monitoring in patients with essential hypertension. Clin Drug Invest. 2003;23:419-430.
29. Chrysant SG, Marbury TC, Robinson TD. Antihypertensive efficacy and safety of olmesartan medoxomil compared with amlodipine for mild-to-moderate hypertension. J Hum Hypertens. 2003;17: 425-432.
30. Schwocho LR, Masonson HN. Pharmacokinetics of CS-866, a new angiotensin II receptor blocker, in healthy subjects. J Clin Pharmacol. 2001;41:515-527.
31. Neutel JM. Clinical studies of CS-866, the newest angiotensin II receptor antagonist. Am J Cardiol. 2001;87 Suppl:37C-43C.
32. Puechler K, Laeis P, Stumpe KO. Blood pressure response, but not adverse event incidence, correlates with dose of angiotensin II antagonist. J Hypertens. 2001;19 Suppl 1:S41-S48.